Neuromod Devices

Neuromod Devices is a pioneer in the development of bimodal neuromodulation treatments, aiming to significantly reduce the suffering of underserved patient populations living with chronic and debilitating conditions globally. The company is committed to designing products that empower patients to take control of their own treatment by delivering targeted therapies that integrate seamlessly into modern lifestyles. Founded in 2010 and headquartered in Ireland, Neuromod has developed and patented a bi-modal neuromodulation technology, which is being evaluated for neurological disorders, including chronic tinnitus, a condition affecting 10% of the adult population. The company achieved a significant milestone with a €15.00M Series B investment at 13 April 2023, led by Fountain Healthcare Partners and Panakes Partners. This investment underlines the confidence of investors in Neuromod's vision and technology, positioning them for continued growth and impact in the Biotechnology and Health Care industries.